Literature DB >> 12774163

Preventive effect of cerivastatin on diabetic nephropathy through suppression of glomerular macrophage recruitment in a rat model.

T Ota1, T Takamura, H Ando, E Nohara, H Yamashita, K Kobayashi.   

Abstract

AIMS/HYPOTHESIS: We investigated the effect of cerivastatin, a statin, on the development of diabetic nephropathy in spontaneously hypertensive rats (SHR) with streptozotocin-induced diabetes.
METHODS: Diabetic SHR were given standard chow or chow containing cerivastatin at a dose of 0.1 mg/kg or 1.0 mg/kg for 12 weeks. Effects of cerivastatin on urinary albumin excretion, mesangial expansion, glomerular macrophage infiltration, and the number of anionic sites on the glomerular basement membrane (GBM) were assessed.
RESULTS: Cerivastatin did not affect the blood glucose concentration, blood pressure or serum cholesterol concentration in diabetic SHR. However, cerivastatin treatment caused a dose-dependent decrease of albuminuria and hyperfiltration. At 1.0 mg/kg, cerivastatin inhibited the diabetes-induced expansion of mesangial and tuft areas on histological examination of the kidneys, as well as the loss of anionic sites from the GBM evaluated with polyetyleneimine and the intraglomerular infiltration of ED1-positive macrophages evaluated by immunohistochemistry. Whole-kidney expression of mRNA for MCP-1 and TGF-beta, estimated by the real-time quantitative RT-PCR, was increased (both 2.6-fold) in untreated diabetic SHR at 12 weeks. Cerivastatin treatment (1.0 mg/kg) inhibited the up-regulated expression of MCP-1 and TGF-beta mRNA (decreased to 48% and 34%, respectively) in diabetic SHR. CONCLUSION/
INTERPRETATION: In this hypertensive model of diabetic nephropathy, cerivastatin decreased albuminuria through suppression of glomerular hyperfiltration, mesangial expansion, and the loss of charge barrier independently of a cholesterol-lowering effect. These preventive effects could be at least partly due to inhibition of macrophage recruitment and activation, and inhibition of TGF-beta overexpression.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12774163     DOI: 10.1007/s00125-003-1099-3

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  37 in total

Review 1.  Regulation of the mevalonate pathway.

Authors:  J L Goldstein; M S Brown
Journal:  Nature       Date:  1990-02-01       Impact factor: 49.962

2.  A high glucose concentration stimulates the expression of monocyte chemotactic peptide 1 in human mesangial cells.

Authors:  C G Ihm; J K Park; S P Hong; T W Lee; B S Cho; M J Kim; D R Cha; H Ha
Journal:  Nephron       Date:  1998       Impact factor: 2.847

3.  Thiazolidinedione derivatives ameliorate albuminuria in streptozotocin-induced diabetic spontaneous hypertensive rat.

Authors:  Haruhisa Yamashita; Yukihiro Nagai; Toshinari Takamura; Erika Nohara; Ken-ichi Kobayashi
Journal:  Metabolism       Date:  2002-04       Impact factor: 8.694

4.  The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.

Authors:  H H Parving; H Lehnert; J Bröchner-Mortensen; R Gomis; S Andersen; P Arner
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

5.  Fluvastatin suppresses oxidative stress and fibrosis in the interstitium of mouse kidneys with unilateral ureteral obstruction.

Authors:  T Moriyama; N Kawada; K Nagatoya; M Takeji; M Horio; A Ando; E Imai; M Hori
Journal:  Kidney Int       Date:  2001-06       Impact factor: 10.612

6.  Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure- and cholesterol-lowering effects.

Authors:  J K Park; D N Müller; E M Mervaala; R Dechend; A Fiebeler; F Schmidt; M Bieringer; O Schäfer; C Lindschau; W Schneider; D Ganten; F C Luft; H Haller
Journal:  Kidney Int       Date:  2000-10       Impact factor: 10.612

7.  Glomerular hemodynamics in experimental diabetes mellitus.

Authors:  T H Hostetter; J L Troy; B M Brenner
Journal:  Kidney Int       Date:  1981-03       Impact factor: 10.612

8.  Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy.

Authors:  T Yamamoto; T Nakamura; N A Noble; E Ruoslahti; W A Border
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

9.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

10.  Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice.

Authors:  K Sharma; Y Jin; J Guo; F N Ziyadeh
Journal:  Diabetes       Date:  1996-04       Impact factor: 9.461

View more
  21 in total

1.  Renoprotective effects of clarithromycin via reduction of urinary MCP-1 levels in type 2 diabetic patients.

Authors:  Atsuhito Tone; Kenichi Shikata; Koichi Nakagawa; Masaaki Hashimoto; Hirofumi Makino
Journal:  Clin Exp Nephrol       Date:  2010-11-03       Impact factor: 2.801

Review 2.  An update on LDL apheresis for nephrotic syndrome.

Authors:  Rupesh Raina; Vinod Krishnappa
Journal:  Pediatr Nephrol       Date:  2018-09-14       Impact factor: 3.714

Review 3.  New pharmacological treatments for improving renal outcomes in diabetes.

Authors:  Anne-Emilie Declèves; Kumar Sharma
Journal:  Nat Rev Nephrol       Date:  2010-05-04       Impact factor: 28.314

4.  Amelioration of nephropathy with apoA-1 mimetic peptide in apoE-deficient mice.

Authors:  Nosratola D Vaziri; Hyun Ju Kim; Hamid Moradi; Farbod Farmand; Kaveh Navab; Mohamad Navab; Susan Hama; Alan M Fogelman; Yasmir Quiroz; Bernardo Rodriguez-Iturbe
Journal:  Nephrol Dial Transplant       Date:  2010-05-20       Impact factor: 5.992

Review 5.  Systemic and renal lipids in kidney disease development and progression.

Authors:  Patricia Wahl; Gloria Michelle Ducasa; Alessia Fornoni
Journal:  Am J Physiol Renal Physiol       Date:  2015-12-23

Review 6.  Monocyte Chemoattractant Protein 1 (MCP-1) in obesity and diabetes.

Authors:  Jun Panee
Journal:  Cytokine       Date:  2012-07-04       Impact factor: 3.861

7.  Simvastatin protects diabetic rats against kidney injury through the suppression of renal matrix metalloproteinase-9 expression.

Authors:  X-M Yao; S-D Ye; Z Zai; Y Chen; X-C Li; G-W Yang; Y-X Wang; K Chen
Journal:  J Endocrinol Invest       Date:  2009-10-09       Impact factor: 4.256

8.  Renoprotective effects of olmesartan medoxomil on diabetic nephropathy in streptozotocin-induced diabetes in rats.

Authors:  Xiaofei Si; Peng Li; Yan Zhang; Yan Zhang; Wei Lv; Dong Qi
Journal:  Biomed Rep       Date:  2013-10-09

9.  Adolescent type 1 Diabetes Cardio-renal Intervention Trial (AdDIT).

Authors: 
Journal:  BMC Pediatr       Date:  2009-12-17       Impact factor: 2.125

10.  Fufang Xue Shuan Tong capsules inhibit renal oxidative stress markers and indices of nephropathy in diabetic rats.

Authors:  Donghong Fang; Xuesi Wan; Wanping Deng; Hongyu Guan; Weijian Ke; Haipeng Xiao; Yanbing Li
Journal:  Exp Ther Med       Date:  2012-08-23       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.